Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 26;271:113854. doi: 10.1016/j.jep.2021.113854

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 5 — the expression level of related proteins and their phosphorylation in the IL-6 mediated JAK-STAT signaling pathway after MXSGD treatment. (A) After MXSGD and IL-6 treatment, the expression level of related proteins and their phosphorylation in the IL-6 mediated JAK-STAT signaling pathway examined by Western blotting assay. (B) The expression level of Bax, Bcl-2 and Caspase 3 after treated with the different concentrations of MXSGD and 50 ng/mL IL-6. (C) The expression level of p-JAK2 after treated with the different concentrations of MXSGD and 50 ng/mL IL-6. (D) The expression level of p-STAT3 after treated with the different concentrations of MXSGD and 50 ng/mL IL-6 (Compared with control group, ##p <0.01. Compared with 50 ng/mL IL-6, *p<0.05, **p <0.01).